ALAltimmune, Inc. ALT · NASDAQ
$2.12 -2.30% (-$0.05)
- Market cap
- $422.1M
- Enterprise value
- $394.8M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 13,616.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -19.5%
- Gross margin
- -48,306.5%
- Net margin
- -296,000.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.18
- Free float
- 94.4%
About the company
Altimmune, Inc. (ALT) is a biotechnology company focused on the development of immunotherapies and therapeutic products. The company specializes in the development of vaccines and therapeutics aimed at boosting the immune system and combating various infectious diseases. Their research spans areas such as respiratory diseases, hepatitis B, and other health challenges. Altimmune strives to innovate in the field of immunotherapy and introduce new treatment possibilities. The company leverages modern technologies and scientific research to achieve its goals. Investors interested in the biotechnology sector and healthcare innovations might see potential in Altimmune, Inc. (ALT) shares for growth in this dynamic field.
Sector
Healthcare
Industry
Biotechnology
CEO
Jerome Benedict Durso
Employees
57
Headquarters
Gaithersburg
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number